Loading
Rhythm Pharmaceuticals, Inc. Stock: price and insider trades · United States
Insider Decl.
597
Thresholds
n/a
Buy Volume
€31M
10 ops. · all time
Sell Volume
€148M
311 ops. · all time
Who traded when
BuySaleSmith Hunter C36 sales
Cramer Pamela J.20 sales
Joseph Shulman20 sales
Jennifer Kayden Lee18 sales
Yann Mazabraud11 sales
David P. Meeker9 sales
+3 other insiders
Since the insiders bought
- -47.0%Entry US$22.24 · Close at T+365 US$11.78
- +6.8%Entry US$24.66 · Close at T+365 US$26.33
- -5.0%Entry US$25.72 · Close at T+365 US$24.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Rhythm Pharmaceuticals, Inc. Strong Buy (bullish), based on 18 analysts. Average price target: US$143.94.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,492 of 26,246 companies
37.8
score / 100
Value27
Quality49
FCF yld-1.9%
Earn yld-3.3%
EV/EBITDA·
ROE-117%
Gross mgn90%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$88.62
Analyst consensus
18 analystsStrong buy
US$120.00Target US$143.94(+62%)US$206.00
Income statement
RevenueUS$189.8M
Gross profitUS$170.3M90% margin
EBITDA-US$174.1M-92% margin
Net income-US$201.9M-85.6% margin
Valuation
PER (forward)-140.9x
P/Book59.2x
Beta2.01
Balance sheet & cash
Market capUS$6.1B
Total debtUS$4M
Free Cash Flow-US$116.6M
Debt / Equity51%
Profitability & ownership
ROE-117.0%
ROA-31.0%
% insiders0.7%
% institutions115.1%
Last declaration on 14 September 2026
Declarations597 total
50,000 shares@ US$104.710.084% mcap100.0% of flowCommonSEC144:0001950047-26-009442
50,000 shares@ US$6.050.0048% mcap3.8% of flowCommon StockSEC:0001649904-26-000026:0
6,439 shares@ US$101.74640.010% mcap8.2% of flowCommon StockSEC:0001649904-26-000026:1
30,746 shares@ US$102.3470.050% mcap39.5% of flowCommon StockSEC:0001649904-26-000026:2
8,698 shares@ US$103.430.014% mcap11.3% of flowCommon StockSEC:0001649904-26-000026:3
1,817 shares@ US$104.54870.0030% mcap2.4% of flowCommon StockSEC:0001649904-26-000026:4
2,300 shares@ US$105.190.0039% mcap3.0% of flowCommon StockSEC:0001649904-26-000026:5
62,774 shares@ US$107.170.098% mcap100.0% of flowCommonSEC144:0001950047-26-008867
1,556 shares@ US$117.07590.0027% mcap20.0% of flowCommon StockSEC:0001649904-26-000013:1
3,400 shares@ US$118.28430.0059% mcap44.1% of flowCommon StockSEC:0001649904-26-000013:2
2,024 shares@ US$6.800.0002% mcap0.3% of flowCommon StockSEC:0001649904-26-000015:0
5,079 shares@ US$119.750.0089% mcap11.9% of flowCommon StockSEC:0001649904-26-000015:1
2,007 shares@ US$116.10930.0034% mcap25.5% of flowCommon StockSEC:0001649904-26-000013:0
800 shares@ US$119.16880.0014% mcap10.4% of flowCommon StockSEC:0001649904-26-000013:3
35,000 shares@ US$24.290.012% mcap7.4% of flowCommon StockSEC:0001649904-26-000009:0
21,601 shares@ US$6.800.0022% mcap1.3% of flowCommon StockSEC:0001649904-26-000009:1
75,834 shares@ US$117.38180.13% mcap77.8% of flowCommon StockSEC:0001649904-26-000009:2
46,625 shares@ US$6.800.0046% mcap3.0% of flowCommon StockSEC:0001649904-26-000007:0
2,300 shares@ US$111.79920.0038% mcap2.5% of flowCommon StockSEC:0001649904-26-000007:1
3,605 shares@ US$114.69550.0061% mcap4.0% of flowCommon StockSEC:0001649904-26-000007:3
14,568 shares@ US$115.4270.025% mcap16.1% of flowCommon StockSEC:0001649904-26-000007:4
18,208 shares@ US$116.49410.031% mcap20.3% of flowCommon StockSEC:0001649904-26-000007:5
17,319 shares@ US$117.46860.030% mcap19.5% of flowCommon StockSEC:0001649904-26-000007:6
1,000 shares@ US$112.8560.0017% mcap1.1% of flowCommon StockSEC:0001649904-26-000007:2
5,079 shares@ US$117.600.0087% mcap100.0% of flowCommonSEC144:0001950047-26-008094
25 of 597 declarations
About Rhythm Pharmaceuticals, Inc.
From October 5 to October 10, 2017, 16 insiders at Rhythm Pharmaceuticals, Inc. bought EUR 87,918,101 in all, which accounts for most of the EUR 88.1 million of the record's 18 purchases (median EUR 6,510,855). Baker Bros. Advisors LP bought EUR 11,570,908 on October 5, New Enterprise Associates 13 LP and Peter J. Barris, both 10% Owner, EUR 7,913,747 each on October 10.
Sales are far more numerous: 311, worth EUR 147.8 million with a median of EUR 164,969, or 5% purchases among open-market trades. Todd Foley, Director, sold EUR 21,004,183 on March 15, 2021 and has 49 filings, 47 of them sales. Jennifer Kayden Lee, EVP, Head of North America, sold EUR 7,718,518 on August 13, 2026, and RA Capital Management, L.P. EUR 3,329,012 on December 3, 2020.
Read moreShow less
The record counts 597 filings from 47 filers, for trades from October 5, 2017 to September 14, 2026, with 207 option exercises, 14 grants and 47 filings of another kind. The year 2021 is the thinnest (4 filings) and 2025 the busiest (145). The US pharmaceutical company, a Nasdaq name, is worth USD 6.1 billion. The past twelve months count 96 filings, 47 of them sales. For 18 purchases a 90-day result is stored: a median of 2.2%, all positive, recorded past results and not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
